A Conversation With Dr Kirsten Bibbins-Domingo, JAMA's New Editor in Chief

A Conversation With Dr Kirsten Bibbins-Domingo, JAMA's New Editor in Chief

In July 2022, Kirsten Bibbins-Domingo, PhD, MD, MAS, took on a new role as the 17th editor in chief of JAMA and the JAMA Network. In conversation with Nobel laureate Harold Varmus, MD, Bibbins-Domingo discusses her research background, approaches to leadership in health care, and the critical role that journals play in communication about public health and science.

Related Content:

Jaksot(124)

Effect of Bifocal and Prismatic Bifocal Spectacles on Myopia Progression in Children: Three-Year Results of a Randomized Clinical Trial

Effect of Bifocal and Prismatic Bifocal Spectacles on Myopia Progression in Children: Three-Year Results of a Randomized Clinical Trial

Interview with Desmond Cheng, OD, MSc, PhD, author of Effect of Bifocal and Prismatic Bifocal Spectacles on Myopia Progression in Children: Three-Year Results of a Randomized Clinical Trial

16 Tammi 20146min

Functional Burden of Strabismus: Decreased Binocular Summation and Binocular Inhibition

Functional Burden of Strabismus: Decreased Binocular Summation and Binocular Inhibition

Interview with Stacy L. Pineles, MD, author of Functional Burden of Strabismus: Decreased Binocular Summation and Binocular Inhibition

14 Marras 20136min

Socioeconomic Disparity in Use of Eye Care Services Among US Adults With Age-Related Eye Diseases

Socioeconomic Disparity in Use of Eye Care Services Among US Adults With Age-Related Eye Diseases

Interview with Jinan Saaddine, MD, MPH, author of Socioeconomic Disparity in Use of Eye Care Services Among US Adults With Age-Related Eye Diseases

12 Syys 20138min

Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4

Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4

Interview with Emily Y. Chew, MD, author of Lutein/Zeaxanthin for the Treatment of Age-Related Cataract: AREDS2 Randomized Trial Report No. 4

11 Heinä 20136min

Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma? PRET Ziada Trial Results

Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma? PRET Ziada Trial Results

Interview with Sheila K. West, PhD, author of Can We Stop Mass Drug Administration Prior to 3 Annual Rounds in Communities With Low Prevalence of Trachoma? PRET Ziada Trial Results

11 Huhti 201311min

Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes

Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes

Interview with Johanna M. Seddon, MD, ScM, author of Validation of a Prediction Algorithm for Progression to Advanced Macular Degeneration Subtypes

14 Helmi 201311min

Risk Alleles in CFH and ARMS2 and the Long-term Natural History of Age-Related Macular Degeneration

Risk Alleles in CFH and ARMS2 and the Long-term Natural History of Age-Related Macular Degeneration

Interview with Ronald Klein, MD, MPH, author of Risk Alleles in CFH and ARMS2 and the Long-term Natural History of Age-Related Macular Degeneration

9 Marras 20126min

The Ophthalmic Practice of the Future

The Ophthalmic Practice of the Future

Interview with Marilyn B. Mets, MD, author of The Ophthalmic Practice of the Future.

10 Syys 201211min

Suosittua kategoriassa Tiede

tiedekulma-podcast
rss-mita-tulisi-tietaa
rss-poliisin-mieli
docemilia
rss-duodecim-lehti
rss-luontopodi-samuel-glassar-tutkii-luonnon-ihmeita
utelias-mieli
rss-astetta-parempi-elama-podcast
filocast-filosofian-perusteet
rss-lapsuuden-rakentajat-podcast
rss-sosiopodi